Abstract
Therapeutic benefits of alpha1-adrenergic antagonists (A1As), namely, prazosin, terazosin and doxazosin, have begun to emerge in a broad range of psychiatric disorders in clinical trials. A1As have shown promise in the treatment of several psychiatric disorders such as posttraumatic stress disorder (PTSD), alcohol dependence, cocaine dependence, nicotine cessation and dementia-related agitation in both animal and human studies. These, and other chronic psychiatric conditions, may be mediated or precipitated by stressful conditions. A1As beneficial effects in these psychiatric disorders are hypothesized via their unique effects on regulating norepinephrine (NE) and corticotrophin releasing factor (CRF), which are two key mediators of stress in the central nervous system (CNS). Despite increasing use of A1As in psychiatric disorders, there is a lack of comprehensive review. Animal studies have suggested that by regulating NE in stressful conditions, A1As can increase the pre-frontal cortical functioning and decrease amygdalar activity. Similarly, rat studies have shown a direct decrease in cerebrospinal fluid (CSF) expression of CRF in rats treated with prazosin in stressful conditions. Thus, A1As may have potential benefit in the treatment and secondary prevention of stress-mediated or precipitated psychiatric disorders. In addition, another beneficial effect of A1As is known to be on improvement of metabolic parameters such as lipid profile and insulin sensitivity.
Keywords: Alpha1-adrenergic receptor antagonists, doxazosin, prazosin terazosin, PTSD, secondary prevention in psychiatric disorders, stress, substance use disorders.
Current Psychopharmacology
Title:Alpha1-Adrenergic Receptor Antagonists Use in Treatment and Prevention of Psychiatric Disorders: A Review
Volume: 3
Author(s): Abhishek Wadhawan, Alok Banga, Yinghui Duan, Michel Mennesson and Zhao Helen Wu
Affiliation:
Keywords: Alpha1-adrenergic receptor antagonists, doxazosin, prazosin terazosin, PTSD, secondary prevention in psychiatric disorders, stress, substance use disorders.
Abstract: Therapeutic benefits of alpha1-adrenergic antagonists (A1As), namely, prazosin, terazosin and doxazosin, have begun to emerge in a broad range of psychiatric disorders in clinical trials. A1As have shown promise in the treatment of several psychiatric disorders such as posttraumatic stress disorder (PTSD), alcohol dependence, cocaine dependence, nicotine cessation and dementia-related agitation in both animal and human studies. These, and other chronic psychiatric conditions, may be mediated or precipitated by stressful conditions. A1As beneficial effects in these psychiatric disorders are hypothesized via their unique effects on regulating norepinephrine (NE) and corticotrophin releasing factor (CRF), which are two key mediators of stress in the central nervous system (CNS). Despite increasing use of A1As in psychiatric disorders, there is a lack of comprehensive review. Animal studies have suggested that by regulating NE in stressful conditions, A1As can increase the pre-frontal cortical functioning and decrease amygdalar activity. Similarly, rat studies have shown a direct decrease in cerebrospinal fluid (CSF) expression of CRF in rats treated with prazosin in stressful conditions. Thus, A1As may have potential benefit in the treatment and secondary prevention of stress-mediated or precipitated psychiatric disorders. In addition, another beneficial effect of A1As is known to be on improvement of metabolic parameters such as lipid profile and insulin sensitivity.
Export Options
About this article
Cite this article as:
Wadhawan Abhishek, Banga Alok, Duan Yinghui, Mennesson Michel and Helen Wu Zhao, Alpha1-Adrenergic Receptor Antagonists Use in Treatment and Prevention of Psychiatric Disorders: A Review, Current Psychopharmacology 2014; 3 (3) . https://dx.doi.org/10.2174/2211556004666150507220211
DOI https://dx.doi.org/10.2174/2211556004666150507220211 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
Call for Papers in Thematic Issues
Breakthroughs in drug design, development and delivery system for the management of neuro-psychiatric disorders
Neuropsychiatric diseases are one of the main causes of disability, affecting millions of people. Various drugs are used for its treatment, although no effective therapy has been found yet. The blood brain barrier (BBB) significantly complicates drugs delivery to the target cells in the brain tissues. This proposal describes the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial: The microRNA 221/222 Cluster: Inaugurating a New Era in Cardiovascular Disease and Cancer?
Current Vascular Pharmacology Economic Aspects on Drug Therapy of Dementia
Current Pharmaceutical Design A Rationale for Curcuminoids for the Prevention or Treatment of Alzheimers Disease
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Estrogen and Cytokines Production - The Possible Cause of Gender Differences in Neurological Diseases
Current Pharmaceutical Design Cholesterol and Dementia: A Long and Complicated Relationship
Current Aging Science Longitudinal Neuropsychological Outcome in Taiwanese Alzheimer's Disease Patients Treated with Medication
Current Alzheimer Research Prostaglandins and Cyclooxygenases in Glial Cells During Brain Inflammation
Current Drug Targets - Inflammation & Allergy Inflammation and Inflammatory Cell Recruitment in Acute Cerebrovascular Diseases
Current Immunology Reviews (Discontinued) The Identification and Characterization of Excitotoxic Nerve-endings in Alzheimer Disease
Current Alzheimer Research Pharmacological Strategies that Affect HIF-1 in the Ischemic Brain: Focus on Hydroxylases Activity and Protein Kinase Pathways
Current Signal Transduction Therapy Reduced Mitochondrial Activity is Early and Steady in the Entorhinal Cortex but it is Mainly Unmodified in the Frontal Cortex in Alzheimer's Disease
Current Alzheimer Research Bioactive Fish Fatty Acids: Health Effects and Their Use as Functional Food Ingredients
Current Nutrition & Food Science Blood Coagulation and the Risk of Atherothrombosis
Current Genomics Role of Nicotinic and Muscarinic Receptors on Synaptic Plasticity and Neurological Diseases
Current Pharmaceutical Design The Neuropharmacology of Cluster Headache and other Trigeminal Autonomic Cephalalgias
Current Neuropharmacology New Directions for Dementia
Current Neurovascular Research Calix[n]arenes as Goldmines for the Development of Chemical Entities of Pharmaceutical Interest
Current Pharmaceutical Design The Role of Cannabinoids in Inflammatory Modulation of Allergic Respiratory Disorders, Inflammatory Pain and Ischemic Stroke
Current Drug Targets COVID-19, the Brain, and the Future: Is Infection by the Novel Coronavirus a Harbinger of Neurodegeneration?
CNS & Neurological Disorders - Drug Targets Mitochondrial Respiration in the Platelets of Patients with Alzheimer’s Disease
Current Alzheimer Research